Key result
DOACs linked to ~37% less major bleeding vs warfarin in elderly non-valvular AF patients.
Why the study?
Major bleeding remains a key concern with oral anticoagulation in older patients with NVAF.
Do DOACs reduce major bleeding compared to warfarin in elderly patients with non-valvular atrial fibrillation?
Cohort (n=886)
No
Do DOACs reduce major bleeding compared to warfarin in elderly patients with non-valvular atrial fibrillation?
In elderly patients with non-valvular atrial fibrillation, DOACs are associated with a lower prevalence of major bleeding compared to warfarin.
Answers are grounded in this paper and cite their sources.
Supports lower major bleeding with DOACs vs warfarin in elderly nonvalvular AF; hypothesis-generating, requires RCT confirmation before practice change.
Background/Objectives: Non-valvular atrial fibrillation (NVAF) is a common arrhythmia in the elderly and carries a high risk of cardioembolic stroke. Oral anticoagulation is central to prevention, with direct oral anticoagulants (DOACs) increasingly replacing warfarin due to better safety and convenience. However, major bleeding remains a key concern, particularly in older patients. This study aimed to determine the prevalence of major bleeding among elderly patients (≥65 years) with NVAF treated with oral anticoagulants. Methods: A retrospective cohort study was conducted on 886 elderly NVAF patients managed at a tertiary hospital between January 2012 and December 2023. Data on demographics, anticoagulant type, comorbidities, and bleeding events were collected. Associations between categorical variables were tested using Chi-square or Fisher’s exact tests, while logistic regression identified predictors of major bleeding. Results: The mean age was 78.4 ± 7.2 years, with equal gender distribution. Most patients (87.1%) received DOACs, while 12.9% were prescribed warfarin. A total of 63 patients (7.1%) experienced major bleeding, including 51 (6.6%) in the DOAC group and 12 (10.5%) in the warfarin group. Intracranial and intra-/retroperitoneal hemorrhages were most common. Logistic regression showed older age, prior bleeding, a higher HASBLED score, and antiplatelet use as significant predictors. Among patients with a recorded weight (n = 70), dosing adherence was better for apixaban and edoxaban compared to dabigatran and rivaroxaban. Conclusions: DOACs were associated with fewer major bleeding events than warfarin. Bleeding risk was strongly linked to age, prior bleeding, HASBLED score, and concomitant antiplatelet therapy, highlighting the importance of appropriate DOAC dosing for safety.
No takes yet. Share an insight, caveat, or question.
Kwan et al. (2025) conducted a cohort in Non-valvular atrial fibrillation (NVAF) (n=886). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Major bleeding. Direct oral anticoagulants were associated with fewer major bleeding events compared to warfarin in elderly patients with non-valvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: